News - ThromboGenics, Xarelto

Filter

Current filters:

ThromboGenicsXarelto

Popular Filters

1 to 25 of 93 results

ThromboGenics announces 2013 growth thanks to Jetrea sales

ThromboGenics announces 2013 growth thanks to Jetrea sales

18-03-2014

Belgium-based biopharma firm ThromboGenics has released its financial results for the full year 2013,…

BelgiumBiotechnologyFinancialJetreaOphthalmicsThromboGenics

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

14-02-2014

There was further negative news for Germany’s Bayer and partner US health care giant Johnson & Johnson,…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

FDA advisory panel nixes approval of J&J and Bayer’s Xarelto for wider use

FDA advisory panel nixes approval of J&J and Bayer’s Xarelto for wider use

17-01-2014

The US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted against…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

17-01-2014

Belgian biotech firm ThromboGenics says that the Transparency Commission of the French National Health…

AlconBiotechnologyJetreaNovartisOphthalmicsPricingThromboGenics

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

ThromboGenics founder Désiré Collen to retire

ThromboGenics founder Désiré Collen to retire

09-12-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen…

BelgiumBoardroomEuropePharmaceuticalThromboGenics

Alcon and ThromboGenics launch Jetrea in Canada

21-11-2013

ThromboGenics NV (Euronext Brussels: THR) and its partner Alcon, the ophthalmic unit of Novartis (NOVN:…

AlconBiotechnologyCanadaJetreaMarkets & MarketingOphthalmicsRegulationThromboGenics

NICE issues final guidance on Jetrea

NICE issues final guidance on Jetrea

23-10-2013

NICE has published final guidance recommending Jetrea (ocriplasmin) from ThromboGenics.

EuropeJetreaOphthalmicsPharmaceuticalRegulationThromboGenics

Germany’s G-BA confirms benefits of ThromboGenics’ Jetrea for VMT

18-10-2013

Belgian biotech firm ThromboGenics says that the Final Early Benefit Assessment from the German Federal…

AlconBiotechnologyEuropeJetreaNovartisOphthalmicsPricingRegulationThromboGenics

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

22-09-2013

Data from the Phase III EINSTEIN clinical trial program published Friday in the Thrombosis Journal underline…

BayerCardio-vascularPharmaceuticalResearchXarelto

ThromboGenics gains rights to DME drug

06-09-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

UK's NICE recommends ThromboGenics' Jetrea for vitreomacular traction

30-08-2013

The UK's National Institute of Health and Care Excellence (NICE) has published final draft guidance recommending…

EuropeHealthcareJetreaOphthalmicsPharmaceuticalThromboGenics

Germany's IQWiG confirms Jetrea's added value for VMT patients

02-08-2013

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the…

BiotechnologyEuropeJetreaOphthalmicsPharmaceuticalPricingRegulationThromboGenics

Bayer reports on anticoagulation reversal activity with PCCs in patients treated with Xarelto

02-07-2013

German pharma major Bayer (BAYN: DE) has today (July 2) revealed results of an open-label, single-center,…

BayerCardio-vascularPharmaceuticalResearchXarelto

1 to 25 of 93 results

Company Spotlight

Fibrotech

Fibrotech

Back to top